The Huntington’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Huntington’s Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Huntington’s Disease Market.
Some of the key takeaways from the Huntington’s Disease Pipeline Report:
Companies across the globe are diligently working toward developing novel Huntington’s Disease treatment therapies with a considerable amount of success over the years.
Huntington’s Disease companies working in the treatment market are Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics, and others, are developing therapies for the Huntington’s Disease treatment
Emerging Huntington’s Disease therapies in the different phases of clinical trials are- TAK-686, Huntington’s Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine, and others are expected to have a significant impact on the Huntington’s Disease market in the coming years.
In December 2023, uniQure N.V. (NASDAQ: QURE), a prominent gene therapy firm dedicated to developing groundbreaking treatments for individuals with critical medical conditions, has unveiled revised interim findings, encompassing a follow-up period of up to 30 months, from 39 participants engaged in the continuing Phase I/II clinical trials of AMT-130 aimed at addressing Huntington’s disease in both the United States and Europe.
In April 2023, Prilenia Therapeutics announced the topline results from the Phase III PROOF-HD clinical trial in Huntington’s Disease.
In August 2022, In order to undertake a Phase I/II trial for its innovative Huntington’s Disease (HD) gene treatment, BV-101, through its subsidiary BrainVectis in France, Asklepios BioPharmaceutical, a fully owned and independently run subsidiary of Bayer AG, got approval. The National Agency for Safety of Medicines and Health Products (ANSM), the nation’s regulatory drug agency, has granted the corporation permission to start seeking volunteers after the relevant Ethics Committee approved the trial protocol.
In March 2022, The PIVOT-HD Phase II clinical trial investigating PTC518 in patients with Huntington’s disease (HD) has begun, according to PTC Therapeutics. An international trial called PIVOT-HD is beginning in the US. PTC518 is a small chemical splicing modifier that may be taken orally and was created specifically to reduce huntingtin mRNA and protein. The underlying cause of HD is not currently being treated.
Huntington’s Disease Overview
Huntington’s disease is a hereditary neurological disorder characterized by progressive degeneration of brain cells, particularly in areas associated with movement, cognition, and behavior. It is caused by a mutation in the HTT gene, leading to the production of abnormal huntingtin protein aggregates in the brain. Symptoms typically manifest in adulthood and worsen over time, including involuntary movements (chorea), cognitive decline, psychiatric symptoms, and impaired motor function.
Get a Free Sample PDF Report to know more about Huntington’s Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/huntingtons-disease-pipeline-insight
Emerging Huntington’s Disease Drugs Under Different Phases of Clinical Development Include:
TAK-686: Sangamo Therapeutics
Huntington’s Disease therapy: Spark therapeutics
CKD-504: Chong Kun Dang Pharmaceutical
NP 001: Neuvivo
rAAV5-miHTT: UniQure Biopharma
WVE003: Wave Life Sciences
Branaplam: Novartis
SAGE-718: Sage Therapeutics
ANX005: Annexon
Valbenazine: Neurocrine Biosciences
Pridopidine: Prilenia Therapeutics
Huntington’s Disease Route of Administration
Huntington’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Huntington’s Disease Molecule Type
Huntington’s Disease Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Huntington’s Disease Pipeline Therapeutics Assessment
Huntington’s Disease Assessment by Product Type
Huntington’s Disease By Stage and Product Type
Huntington’s Disease Assessment by Route of Administration
Huntington’s Disease By Stage and Route of Administration
Huntington’s Disease Assessment by Molecule Type
Huntington’s Disease by Stage and Molecule Type
DelveInsight’s Huntington’s Disease Report covers around 50+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Huntington’s Disease product details are provided in the report. Download the Huntington’s Disease pipeline report to learn more about the emerging Huntington’s Disease therapies
Some of the key companies in the Huntington’s Disease Therapeutics Market include:
Key companies developing therapies for Huntington’s Disease are – Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others.
Huntington’s Disease Pipeline Analysis:
The Huntington’s Disease pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Huntington’s Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Huntington’s Disease Treatment.
Huntington’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Huntington’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Huntington’s Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Huntington’s Disease drugs and therapies
Huntington’s Disease Pipeline Market Drivers
Introduction of disease-modifying drugs, further understanding in pathogenesis are some of the important factors that are fueling the Huntington’s Disease Market.
Huntington’s Disease Pipeline Market Barriers
However, lesser approved therapies, stringent regulations and other factors are creating obstacles in the Huntington’s Disease Market growth.
Scope of Huntington’s Disease Pipeline Drug Insight
Coverage: Global
Key Huntington’s Disease Companies: Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics, and others
Key Huntington’s Disease Therapies: TAK-686, Huntington’s Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine, and others
Huntington’s Disease Therapeutic Assessment: Huntington’s Disease current marketed and Huntington’s Disease emerging therapies
Huntington’s Disease Market Dynamics: Huntington’s Disease market drivers and Huntington’s Disease market barriers
Request for Sample PDF Report for Huntington’s Disease Pipeline Assessment and clinical trials
Table of Contents
1. Huntington’s Disease Report Introduction
2. Huntington’s Disease Executive Summary
3. Huntington’s Disease Overview
4. Huntington’s Disease- Analytical Perspective In-depth Commercial Assessment
5. Huntington’s Disease Pipeline Therapeutics
6. Huntington’s Disease Late Stage Products (Phase II/III)
7. Huntington’s Disease Mid Stage Products (Phase II)
8. Huntington’s Disease Early Stage Products (Phase I)
9. Huntington’s Disease Preclinical Stage Products
10. Huntington’s Disease Therapeutics Assessment
11. Huntington’s Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Huntington’s Disease Key Companies
14. Huntington’s Disease Key Products
15. Huntington’s Disease Unmet Needs
16 . Huntington’s Disease Market Drivers and Barriers
17. Huntington’s Disease Future Perspectives and Conclusion
18. Huntington’s Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Guarav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/